Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth PPOB Formulary Coverage & PA | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    PPO Preferred Plan Formulary — Drugs Covered (Formulary — PPOB)

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the EmblemHealth PPO Preferred Plan drug formulary (list of covered drugs) as of Apr 1, 2026 and explains coverage tiers, limits, prior authorization, and how members/providers can use the formulary. It affects members and providers covered under the PPOB formulary.

    Policy Summary
    PayerEmblemHealth
    PolicyPPO Preferred Plan Formulary — Drugs Covered
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization when a product is marked 'PA' to avoid coverage denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    PPOBFormulary/plan
    2026-04-01Effective
    PA, QL, SP, ST, LAUtilization flags
    ACAACA $0 tier
    204Common QL example

    Coverage Criteria and Formulary Listings

    General Coverage Principles

    Coverage and utilization management apply as follows:

    Formulary coverage basics: Drugs listed on the formulary may have tier assignments and utilization management flags (e.g., PA, QL, ST) and special designations (ACA preventive tier, SP, LA). Presence on the formulary does not guarantee payment — coverage is subject to the member's Certificate of Coverage and plan-specific rules.

    Members/providers should consult the Certificate of Coverage or Member Services (833-998-5430, TTY 711) for plan-specific coverage and copay details.

    Formulary coverage (listing)

    Covered products with administrative qualifiers

    Formulary listing node: Each product row lists the drug name, available strengths, Drug Tier, and any Requirements/Limits flags such as PA (Prior Authorization), QL (Quantity Limit), OTC, SP (Specialty), LA (Limited Availability), or ACA (preventive $0 tier). Presence on the list indicates the drug is covered subject to those annotations and plan terms.

    No clinical necessity decision trees are present in this extract; follow the listed Requirements/Limits for claims and prior authorization.

    Policy Summary
    PayerEmblemHealth
    PolicyPPO Preferred Plan Formulary — Drugs Covered
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization when a product is marked 'PA' to avoid coverage denial.
    SourceLink
    On This Page
    Coverage Criteria and Formulary ListingsCode Lists, Formulary Entries and Quantity FlagsPrior Authorization, Documentation and Billing RequirementsAbbreviations and DefinitionsStep Therapy Rules and FlagsQuantity Limits by ProductSite of Care and Specialty HandlingBackground and Scope

    Formulary coverage with utilization controls

    Coverage entries and constraints as listed in formulary lines (per product):

    Formulary coverage line: Each formulary line specifies the product and its utilization controls. Examples in this extract include drugs with PA (e.g., GLP‑1 agents like MOUNJARO, OZEMPIC, TRULICITY), and quantity limits for many insulins and oral agents (e.g., QL 4 pens/28 days; QL 33 pens/30 days; QL 10 vials/30 days).

    Providers must obtain PA when Requirements/Limits = PA and must observe the stated QL when submitting claims; exceeding QL may result in denial or require PA.

    Coverage mapping by tier/flags

    Coverage guidance as expressed by Drug Tier and Requirements/Limits entries in this fragment

    Formulary listing rules: Coverage is determined by the assigned Drug Tier and the Requirements/Limits flags: ACA indicates preventive/$0 tier for eligible vaccines and agents; OTC marks over‑the‑counter products; QL denotes specific quantity limits (e.g., 204 strips/30 days for many test strips); SP and LA indicate specialty handling or limited‑availability items that may require additional authorization or site‑of‑care considerations.

    Exact clinical PA criteria are not included in this excerpt — follow the Requirements/Limits field and full policy for authorization details.

    A medicine appearing on this formulary is not an absolute guarantee of coverage for every member. Coverage depends on the member’s specific benefit plan and the plan’s Certificate of Coverage. The formulary may list utilization controls (for example, PA for prior authorization or QL for quantity limits) that must be satisfied before a claim will be paid. Members and providers should check benefit details and contact Member Services for plan‑specific copay and coverage rules.

    This segment of the formulary excerpt does not contain additional explicit coverage criteria beyond the product listings, tiers, and Requirements/Limits shown on each line. Where no Requirements/Limits are listed, coverage is still subject to the member’s Certificate of Coverage and any plan‑level rules.

    Some entries are designated OTC in the Requirements/Limits column, indicating over‑the‑counter availability and differing coverage handling. Examples in this extract include oral glucose products, many glucose test strips, and alcohol preps. OTC designation may mean no prescription is required and that coverage and quantity rules follow the OTC handling shown on the product line.

    This fragment does not state clinical exclusions by diagnosis; instead, coverage is expressed via product flags and limits. Several items carry administrative designations such as LA (limited availability), SP (specialty), and QL (quantity limits) which may restrict how or where products are provided and require additional authorization or specialty pharmacy handling.

    No explicit additional policy statements or expanded clinical rules are present in this segment beyond the line‑item Requirements/Limits (e.g., OTC, QL) and tier assignments shown on each formulary row.

    This extract does not include statements labeling items as 'Not Medically Necessary.' Coverage determinations are indicated by tier and the Requirements/Limits flags on each product line.

    Within the provided segments there are no explicit product lines or language declaring therapies or supplies as 'Not Medically Necessary.' The document uses tiering and administrative flags (PA, QL, OTC, SP, LA) to communicate coverage controls instead.

    This fragment does not identify any items as explicitly Not Medically Necessary. Instead, preventive and commonly used items (for example, selected prenatal vitamins, smoking‑cessation aids, and aspirin products) are listed with Drug Tier assignments and, when applicable, OTC flags or other Requirements/Limits.

    Code Lists, Formulary Entries and Quantity Flags

    Selected drugs and vaccines listedmixed
    APRETUDEcabotegravir im extended release susp 600 mg/3ml
    DESCOVYemtricitabine-tenofovir alafenamide fumarate tab 200-25 mg
    Truvadaemtricitabine-tenofovir disoproxil fumarate tab 200-300 mg
    YEZTUGOlenacapavir sodium tab 300 mg; subcutaneous soln 463.5 mg/1.5ml
    ABRYSVOrsv pre-fusion f a&b vac recomb for im soln 120 mcg/0.5ml
    ACTHIBhaemophilus b polysaccharide conjugate vaccine for inj
    COMIRNATYcovid-19 mrna vac tris-pfizer im susp pref syr (various strengths)
    GARDASIL 9human papillomavirus (hpv) 9-valent recomb vac susp pref syr
    PREVNAR 20pneumococcal 20-valent conjugate vaccine sus pref syr 0.5 ml
    Vaccines and immunizing agentsNDC-likeCovered
    VACCINcovid-19 mrna vaccine-moderna im susp pref syr 10 mcg/0.2ml
    MRESVIArsv mrna pre-f vaccine im susp pref syr 50 mcg/0.5ml
    NUVAXOVIDcovid-19 subunit vacc-novavax im susp pref syr 5 mcg/0.5ml
    PEDVAX HIBhaemophilus b polysaccharide conj vac im susp 7.5 mcg/0.5 ml
    PENBRAYAmeningococcal acyw (tet conj)-mening b (rcmb) vacc for inj
    PNEUMOVAX 23pneumococcal vaccine polyvalent soln pref syr 25 mcg/0.5ml
    PREVNAR 20pneumococcal 20-valent conjugate vaccine sus pref syr 0.5 ml
    SHINGRIXzoster vac recombinant adjuvanted for im inj 50 mcg/0.5ml
    Vaccines/toxoids and contraceptive devicesNDC-likeCovered
    ADACELtet tox-diph-acell pertuss ad inj 5-2-15.5 lf-lf-mcg/0.5ml
    BOOSTRIXtet-diph-acell pertuss ad pref syr 5-2.5-18.5 lf-mcg/0.5ml
    ANNOVERAsegesterone ace-ethinyl estradiol va ring 0.15-0.013 mg/24hr
    KYLEENAlevonorgestrel releasing iud 17.5 mcg/day (19.5 mg total)
    MIRENAlevonorgestrel iud 20 mcg/day (initial) (52 mg total)
    NEXPLANONetonogestrel subdermal implant 68 mg
    PARAGARD INTRAUTERINE COPcopper iud
    Antidiabetics and related agentsNDC-likeCovered
    FARXIGAdapagliflozin propanediol tab 5 mg, 10 mg
    GLIMEPIRIDEglimepiride tab 1 mg, 2 mg, 4 mg
    GLIPIZIDEglipizide tab 2.5 mg (and ER formulations)
    BAQSIMIglucagon nasal powder 3 mg/dose
    MOUNJAROtirzepatide soln auto-injector (multiple strengths)
    OZEMPICsemaglutide soln pen-inj (multiple strengths)
    JANUMETsitagliptin phosphate-metformin hcl tab 50-500 mg, 50-1000 mg
    Formulary drug entries (partial)mixed
    JANUVIAsitagliptin phosphate tab 25 mg, 50 mg, 100 mg; Drug Tier = 2; Requirements/Limits = .
    JARDIANCEempagliflozin tab 10 mg, 25 mg; Drug Tier = 2; Requirements/Limits = QL (30 tablets/30 days).
    mifepristone (Korlym)tab 300 mg; Drug Tier = 1; Requirements/Limits = PA, QL (120 tablets/30 days), SP
    MOUNJAROtirzepatide soln auto-injector (various strengths); Drug Tier = 2; Requirements/Limits = PA, QL (4 pens/180 days or 4 pens/28 days depending on strength).
    OZEMPICsemaglutide soln pen-inj (various strengths); Drug Tier = 2; Requirements/Limits = PA, QL (1 pen/28 days or 3 pens/28 days depending on strength).
    RYBELSUSsemaglutide tab (3 mg, 7 mg, 14 mg); Drug Tier = 2; Requirements/Limits = PA, QL (30 tablets/30 or 180 days depending on dose).
    SOLIQUA 100/33insulin glargine-lixisenatide sol pen-inj; Drug Tier = 2; Requirements/Limits = QL (6 pens/30 days).
    SYNJARDY / SYNJARDY XRempagliflozin-metformin combinations; Drug Tier = 2; Requirements/Limits = QL (30-60 tablets/30 days varying by strength).
    TRIJARDY XRempagliflozin-linagliptin-metformin er; Drug Tier = 2; Requirements/Limits = QL (30-60 tablets/30 days).
    TRULICITYdulaglutide soln auto-injector (0.75,1.5,3,4.5 mg); Drug Tier = 2; Requirements/Limits = PA, QL (varies: 4 pens/28 days or 2 pens/28 days).
    1–10 of 22
    1/3
    Formulary Flags and Quantity Limitsmixed
    QL (204 strips/30 days)Quantity limit for many glucose test strips as shown (e.g., CONTOUR, FREESTYLE, PRECISION XTRA)
    QL (120 films/30 days)Quantity limit for Suboxone film 2-0.5 mg
    QL (60 tablets/30 days)Quantity limit for buprenorphine hcl-naloxone 8-2 mg tablets
    LALimited access designation (appears for BRIXADI, SUBLOCADE)
    SPSpecialty designation (appears for SUBLOCADE, VIVITROL)
    OTCOver-the-counter requirement/limit flag
    Product lines (no CPT/HCPCS present in this segment)mixed
    No codes listed
    Formulary items listed in excerptmixed
    V-GO 20insulin infusion disposable pump kit 20 unit/24hr
    V-GO 30insulin infusion disposable pump kit 30 unit/24hr
    V-GO 40insulin infusion disposable pump kit 40 unit/24hr
    VARISOFT INFUSION SET/23"insulin infusion pump supplies - infusion set
    VARISOFT INFUSION SET/32"insulin infusion pump supplies - infusion set
    VARISOFT INFUSION SET/43"insulin infusion pump supplies - infusion set
    WEBCOL ALCOHOL PREP LARGEalcohol swabs
    WEBCOL ALCOHOL PREP MEDIUalcohol swabs
    WIDE-SEAL SILICONE DIAPHRdiaphragm wide seal (various sizes)
    ZEVRX STERILE ALCOHOL PREalcohol swabs
    Diabetes monitoring and infusion suppliesmixed
    DEXCOM G7 15 DAY SENSORcontinuous glucose monitor sensor
    DEXCOM G6 SENSORcontinuous glucose monitor sensor
    DEXCOM G6 TRANSMITTERCGM transmitter
    DEXCOM G7 RECEIVERCGM receiver
    EXTENDED INFUSION SET 23"extended infusion set
    EXTENDED INFUSION SET 32"extended infusion set
    EXTENDED INFUSION SET 43"extended infusion set
    EXTENDED RESERVOIR 3.0 MLinfusion reservoir
    inv-22: Quantity limits — examples: QL (30 tablets/30 days); QL (4 pens/28 days); QL (4 pens/180 days)
    ExamplesQL (30 tablets/30 days); QL (4 pens/28 days); QL (4 pens/180 days)
    Common tablet QL30 tablets per 30 days (e.g., FARXIGA, JARDIANCE)
    Common pen QL4 pens per 28 days or 4 pens per 180 days depending on product strength (e.g., MOUNJARO)
    inv-23: Example QL thresholds — multiple pen/tablet/vial thresholds listed
    Pen/vial examples1 pen/28 days; 3 pens/28 days; 4 pens/28 days; 4 pens/180 days; 6 pens/30 days
    Tablet examples60 tablets/30 days (JANUMET); 30 tablets/30 days (FARXIGA, GLYXAMBI)
    Vial example10 vials/30 days (NOVOLOG Mix 70/30 vials example)
    inv-24: Test strip monthly limit — 204 strips/30 days
    Monthly test strip limit204 strips per 30 days
    Applies toMany glucose test strip products (e.g., CONTOUR, FREESTYLE, PRECISION XTRA)
    Requirements/Limits flagOTC, QL (204 strips/30 days)
    inv-25: Test strip monthly limit (duplicate reference) — 204 strips/30 days
    Monthly test strip limit (duplicate)204 strips per 30 days
    Representative productsFREESTYLE LITE, FREESTYLE PRECISION NEO B, PRECISION XTRA (listed with QL 204/30 days)
    FlaggingRequirements/Limits = OTC, QL (204 strips/30 days)
    inv-26: Sensors/Pods/Receivers limits — examples: 3 sensors/30 days; 2 sensors/30 days; 1 receiver/365 days; 30 pods/30 days
    Sensors/Pods/Receivers examples3 sensors/30 days (Dexcom G6/G7); 2 sensors/30 days (G7 15-day variant); 1 receiver/365 days; 30 pods/30 days (Omnipod)
    Transmitters/receiversTransmitters listed with QL (e.g., 1 transmitter/90 days) and receivers with QL (1 receiver/365 days)
    Pod refill limit30 pods per 30 days for Omnipod/Dexcom-integrated pod products
    inv-27: Disposable pump kit limit — 30 systems/30 days (V-GO), 1 kit/720 days (some pump kits)
    Disposable pump systems (V-GO)QL (30 systems/30 days)
    Starter/intro kit limitSome pump/intro kits listed with QL (1 kit/720 days) (e.g., Omnipod/ILET starter kits)
    Omnipod kit exampleOMNIPOD DASH INTRO KIT and OMNIPOD 5 kits: Requirements/Limits = PA, QL (1 kit/720 days)

    Prior Authorization, Documentation and Billing Requirements

    Prior Authorization

    Prior Authorization, Documentation and Billing Requirements

    Prior Authorization Required. Certain drugs and supplies listed in this formulary require prior authorization (PA) before the plan will cover them. If prior authorization is not obtained, the claim may be denied.

    • Examples of drugs requiring PA: mifepristone (PA, QL, SP), MOUNJARO (PA, QL), OZEMPIC (PA, QL), TRULICITY (PA indicated where listed), many GLP agents
    • Specialty or limited-access products (flagged SP or LA) may have additional PA criteria (e.g., extended-release buprenorphine products such as BRIXADI are LA and SP)
    • Prior authorization is required for specified insulin pumps and pump kits (e.g., ILET pump and starter kits, OMNIPOD intro kits, OMNIPOD 5 kits, TWIIST starter kit)
    • V-GO disposable pump kits (V-GO 20/30/40) require PA and are subject to quantity limits (PA, QL — typically QL (30 systems/30 days) or as listed)
    • PA applies to other specialty injectable or extended-release formulations as indicated on the formulary rows
    Denial Risk

    Prior authorization / Quantity limit triggers

    Prior authorization and Quantity Limits (QL). Requests that exceed published quantity limits or that lack required PA documentation may be denied. Follow the Requirements/Limits field on each formulary row when submitting claims or PA requests.

    • Examples of QL enforcement: FARXIGA (QL 30 tablets/30 days), JANUMET/XR (QL 60 or 30 tablets/30 days), insulin pens/cartridges (various QL values), CGM supplies (e.g., test strips QL 204/30 days)
    • Pump/kits QL examples: ILET pump (PA, QL 1 kits/720 days), OMNIPOD intro kits (PA, QL 1 kit/720 days), OMNIPOD pods (PA, QL 30 pods/30 days), V-GO kits (PA, QL 30 systems/30 days)
    • GLP and tirzepatide agents show PA plus pen/pen-count QLs (MOUNJARO: PA, QL 4 pens/28 or 180 days; OZEMPIC: PA, QL 1–3 pens/28 days depending on strength)
    Documentation Required

    Documentation expectations for PA/QL/LA/SP items

    Documentation expectations for PA/QL/LA/SP items. When a formulary entry lists PA, QL, LA (Limited Access) or SP (Specialty), provide clinical justification and supporting documentation with the PA submission. Use the plan's PA forms and include relevant clinical notes, prior therapies tried, and dosing/quantity rationale.

    • Include diagnosis, prior treatment history, and reason for the requested drug or device; for specialty drugs include monitoring plan and handling requirements
    • For QL exceptions or requests exceeding the stated limit, provide rationale and supporting clinical information
    • For LA/SP products, include documentation that the member requires the specialty formulation or product and that standard alternatives are inappropriate or contraindicated
    Billing Rule

    Claims and PA documentation

    Claims and PA documentation. Pharmacy claims must include accurate NDC and days' supply consistent with the formulary QL. When 'PA' is indicated on the formulary row, ensure PA fields are populated on the claim or a PA has been submitted and approved prior to dispensing.

    • Populate PA fields on the claim when a formulary row indicates 'PA' to avoid adjudication failure
    • Verify NDC, quantity, and days' supply match the approved PA; mismatches may result in denial or reversal
    • For device/supply items billed under medical benefit, include HCPCS/CPT as appropriate and attach PA approval when filing claims
    Prior Authorization

    PA required for pumps/kits

    Required documentation for PA for pumps and pump kits. Prior authorization submissions for insulin pumps and disposable pump kits must include clinical justification, history of insulin therapy, evidence of frequent glucose monitoring or hypoglycemia as applicable, and prior therapy attempts when requested.

    • Specific pump/kits requiring PA: ILET insulin pump and starter kits (PA, QL), OMNIPOD DASH/OMNIPOD 5 kits and pods (PA, QL), OMNIPOD INTRO KIT, TWIIST starter kit (PA where listed)
    • Supply frequency and device replacement intervals are governed by QL (e.g., 1 kit/720 days for many pumps; pods often QL 30 pods/30 days)
    • Include physician order, pump training plan, and supplier details with PA submission
    Note

    Special program requirements

    Special program requirements and specialty/limited-access flags. Products flagged with 'SP' (Specialty) or 'LA' (Limited Access) may require enrollment in a specialty program, specialty pharmacy dispensing, or additional monitoring and documentation.

    • BRIXADI buprenorphine extended-release products are flagged LA and SP and have special handling and dispensing requirements
    • Some agents (e.g., certain injectable or extended-release formulations) may only be available through contracted specialty pharmacies
    Denial Risk

    Prior authorization indicated; Quantity limit enforcement

    Quantity limit enforcement and PA indicated. Dispensing beyond stated quantity limits or without required PA may result in denial. Review the Requirements/Limits column for each product and obtain PA when 'PA' is shown.

    • Examples: test strips often limited to 204 strips/30 days; many insulins have pen/cartridge QLs; GLP agents and tirzepatide have pen-count QLs tied to strength
    • V-GO kits and OMNIPOD kits explicitly list both PA and QL — ensure both approval and correct quantity to avoid denial
    Note

    No explicit authorization or denial rule

    No explicit authorization or denial rules in some formulary rows. Certain segments of the formulary simply list product names, tiers, or OTC status without an explicit PA, QL, ST, LA or SP indicator; these entries do not imply PA is required unless noted elsewhere.

    • When a product row does not list PA, QL, LA or SP, standard coverage rules and the member's Certificate of Coverage apply
    • If in doubt, verify coverage and authorization requirements by contacting Member Services or checking plan-specific documents
    Step Therapy

    Step therapy not specified / Step therapy flags

    Step therapy and step-therapy flags. While many formulary rows do not specify step therapy sequences, some device/sensor items are marked 'ST' indicating step therapy requirements; absent an ST flag, step therapy is not specified in that segment.

    • Examples: Dexcom G6/G7 receivers, sensors and transmitters include ST flags along with QLs (e.g., QL limits for receivers/sensors/transmitters and ST designation)
    • Most drug rows in the provided segments do not list step therapy sequences — follow the Requirements/Limits field and plan documents for any ST rules
    Note

    Contact for assistance

    How to get help. For plan-specific coverage, PA forms, or assistance with prior authorization submissions, contact EmblemHealth Member Services. The member's Certificate of Coverage remains the definitive source for benefit details.

    • EmblemHealth Member Services: 833-998-5430 (TTY: 711) — 24/7 assistance
    • Refer to the member portal (my.emblemhealth.com) and the Certificate of Coverage for plan-specific details and PA form access

    Abbreviations and Definitions

    inv-64: Generic vs Brand — generic vs brand naming/format guidance
    Format guidanceBrand prescription drugs are shown in capital letters; generic drugs are shown in lower-case boldface
    DefinitionGeneric drugs are lower-cost versions of brand-name drugs
    Filling practice notePharmacists generally fill generics when available unless prescriber specifies otherwise (format signals generic vs brand)
    inv-65: Abbreviations — ACA, PA, QL, SP, ST, LA definitions referenced
    Abbreviations listACA, PA, QL, SP, ST, LA, OTC
    ACAAffordable Care Act — $0 cost share preventive drugs (may have limits)
    FFFrozen Formulary (coverage or copay may change depending on plan year)
    inv-66: PA — Prior Authorization requires approval before coverage
    DefinitionPA: Prior Authorization — the plan requires approval before filling; without approval the plan may not cover the drug
    Provider actionSubmit PA with clinical justification when Requirements/Limits = PA (e.g., MOUNJARO, OZEMPIC)
    Claims notePA codes/fields must be populated on the claim when PA is listed
    inv-67: QL — Quantity Limit definition and examples
    DefinitionQL: Quantity Limit — a maximum quantity the plan will cover for a specified time period (e.g., 30 tablets/30 days)
    ExamplesShown as QL (204 strips/30 days), QL (33 pens/30 days), QL (4 pens/28 days)
    Claims implicationDispensing beyond the QL may be denied or require PA
    inv-68: LA — Limited Availability or site-specific administration
    DefinitionLA: Limited Availability — product may only be available at select pharmacies or sites; may indicate site-specific administration
    ExamplesUsed for certain IUDs (MIRENA, LILETTA) and long-acting injectables listed with LA
    Coverage noteLA may require specific dispensing location or additional authorization
    inv-69: SP — Specialty Pharmacy handling required
    DefinitionSP: Specialty Pharmacy — indicates specialty handling, monitoring, or distribution is required
    ExamplesListed for products like BEYFORTUS, BRIXADI, SUBLOCADE and some injectable biologics
    Provider actionSpecialty products may require PA and specialty pharmacy fulfillment
    inv-70: OTC — Over-the-counter designation
    DefinitionOTC: Over-the-counter — non-prescription products; may be covered and are flagged as OTC in Requirements/Limits
    ExamplesMany glucose gels, lancets, alcohol swabs, and some nicotine replacement products are OTC
    Coverage implicationOTC flag indicates different coverage handling compared with prescription drugs
    inv-71: PA definition (duplicate) — Prior Authorization — coverage requires advance approval
    Definition (duplicate)PA: Prior Authorization — coverage requires advance approval
    ExamplesMOUNJARO, OZEMPIC, TRULICITY appear with PA flag in product lines
    ConsequenceFailure to obtain PA may result in non-coverage
    inv-72: QL — Quantity Limit definition (duplicate) — maximum per period
    Definition (duplicate)QL: Quantity Limit — maximum quantity allowed per specified time period (e.g., 30 tablets/30 days)
    Test strip exampleQL (204 strips/30 days)
    Device exampleQL (3 sensors/30 days; 1 receiver/365 days)
    inv-73: OTC definition (duplicate) — Over-the-counter coverage notes
    Definition (duplicate)OTC: Over-the-counter — available without prescription and may be listed as OTC in Requirements/Limits
    ExamplesGlucose gels, many test strips, alcohol swabs are shown as OTC in Requirements/Limits
    Coverage noteOTC designation may affect how product is paid or where it is obtained
    inv-74: QL example — quantity limit specified for product (e.g., 204 strips/30 days)
    Example QL entryQL (204 strips/30 days) — quantity limit specified for product lines such as glucose test strips
    Applies toMultiple glucose test strip brands listed with QL 204/30 days
    FlaggingRequirements/Limits = OTC, QL (204 strips/30 days)
    inv-75: SP / LA — Specialty or limited access designation notes
    SP / LA notesProducts flagged SP or LA indicate specialty or limited access handling and may require PA or specialty pharmacy fulfillment
    ExamplesBRIXADI, SUBLOCADE, some vaccine or biologic passive immunizing agents (BEYFORTUS) are shown with SP/LA
    Provider actionFollow Requirements/Limits field for dispensing and PA submission when SP/LA is present
    inv-76: OTC — Requirements/Limits = OTC indicating non-prescription availability
    OTC contextOTC indicates non-prescription availability; many consumables (e.g., alcohol swabs, lancets) listed as OTC
    ExamplesGlucose gels, glucose chew tabs, alcohol prep pads listed with Requirements/Limits = OTC
    Coverage implicationOTC items may still have QL flags (e.g., test strips) despite OTC status

    Step Therapy Rules and Flags

    Step therapy summary
    Step therapy (ST) may require trying specified first-line drugs before the plan will cover another drug for the same condition (member must trial preferred agent(s) first).
    Step therapy summary
    This segment does not provide explicit step therapy sequences; formulary lines shown include Prior Authorization (PA) and Quantity Limit (QL) flags but no ST rules are specified here.
    Step therapy summary
    Several GLP-1 receptor agonists and related agents are listed with Prior Authorization (PA) and Quantity Limits (e.g., MOUNJARO = PA, QL (4 pens/180 days or 4 pens/28 days depending on strength); OZEMPIC = PA, QL (1 pen/28 days or 3 pens/28 days)). An explicit step sequence is not provided in these lines.
    Step therapy summary
    No explicit step therapy steps are listed for specialty or long‑acting products in this fragment; entries show Requirements/Limits flags such as LA (Limited Availability), SP (Specialty), and QL (Quantity Limit) but do not define ST sequences.
    ProductRequirements/Limits (ST indicated)
    {"text":"DEXCOM G6 RECEIVER","status":""},{"text":"QL (1 receiver/365 days), ST","status":""}
    {"text":"DEXCOM G6 SENSOR","status":""},{"text":"QL (3 sensors/30 days), ST","status":""}
    {"text":"DEXCOM G6 TRANSMITTER","status":""},{"text":"QL (1 transmitter/90 days), ST","status":""}
    {"text":"DEXCOM G7 RECEIVER","status":""},{"text":"QL (1 receiver/365 days), ST","status":""}
    {"text":"DEXCOM G7 SENSOR","status":""},{"text":"QL (3 sensors/30 days), ST","status":""}
    {"text":"DEXCOM G7 15 DAY SENSOR","status":""},{"text":"QL (2 sensors/30 days), ST","status":""}

    Quantity Limits by Product

    inv-85: DESCOVY — 30 tablets
    DESCOVY quantity limit30 tablets per 30 days
    ContextListed under ANTIVIRALS with Requirements/Limits = QL (30 tablets/30 days)
    TierDrug Tier = ACA for DESCOVY in this listing
    inv-86: Truvada — 30 tablets
    Truvada quantity limit30 tablets per 30 days
    Contextemtricitabine-tenofovir disoproxil fumarate (Truvada) listed with QL (30 tablets/30 days)
    TierDrug Tier = ACA in this listing
    inv-87: YEZTUGO (oral) — 4 tablets
    YEZTUGO (oral) quantity limit4 tablets per 365 days
    Alternate formulationYEZTUGO subcutaneous formulation is listed separately and flagged SP
    TierDrug Tier = ACA
    inv-88: FARXIGA — 30 tablets
    FARXIGA quantity limit30 tablets per 30 days
    Drug classSGLT2 inhibitor (dapagliflozin)
    TierDrug Tier = 2
    inv-89: GLYXAMBI — 30 tablets
    GLYXAMBI quantity limit30 tablets per 30 days
    Compositionempagliflozin-linagliptin combination
    TierDrug Tier = 2
    inv-90: MOUNJARO — 4 pens
    MOUNJARO pens4 pens per applicable period (4 pens/28 days or 4 pens/180 days depending on strength)
    PA flagMOUNJARO listed with PA in product lines
    TierDrug Tier = 2
    inv-91: MOUNJARO (other strengths) — 4 pens
    MOUNJARO (other strengths)4 pens per 28 days (for certain strengths)
    Alternate interval4 pens per 180 days for lower-dose initiation strength in other listing
    RequirementsPA, QL as listed per strength
    inv-92: OZEMPIC — 1 pen/28 days or 3 pens/28 days depending on strength
    OZEMPIC pens1 pen/28 days or 3 pens/28 days depending on strength
    PA flagOZEMPIC listed with PA
    TierDrug Tier = 2
    inv-93: JANUMET / JANUMET XR — 60 tablets/30 days (JANUMET) or 30 tablets/30 days (XR)
    JANUMET (regular) quantity limit60 tablets per 30 days
    JANUMET XR (extended release)30 tablets per 30 days
    TierDrug Tier = 2
    inv-94: MOUNJARO — 4 pens (repeated entry)
    MOUNJARO quantity limit (repeat)4 pens per listed period
    Strength-specific intervals4 pens/28 days or 4 pens/180 days depending on strength
    PA requirementPA indicated for MOUNJARO
    inv-95: MOUNJARO (other strengths) — 4 pens (repeated)
    MOUNJARO (other strengths) repeat4 pens per period as listed
    See product lineRequirements/Limits show PA and QL per strength
    TierDrug Tier = 2
    inv-96: OZEMPIC — 1 or 3 pens
    OZEMPIC (summary)1 or 3 pens per 28 days depending on strength
    PA requirementPA listed for OZEMPIC
    TierDrug Tier = 2
    inv-97: SOLIQUA 100/33 — 6 pens
    SOLIQUA 100/336 pens per 30 days
    CompositionInsulin glargine-lixisenatide combination
    TierDrug Tier = 2
    inv-98: FIASP — 10 vials
    FIASP vials limit10 vials per 30 days
    FIASP pens (FlexTouch)33 pens per 30 days (FIASP FLEXTOUCH)
    TierDrug Tier = 2
    inv-99: FIASP FLEXTOUCH — 33 pens
    FIASP FLEXTOUCH limit33 pens per 30 days
    FormulationInsulin aspart (with niacinamide) pen-injector 100 unit/ml
    TierDrug Tier = 2
    inv-100: TOUJEO SOLOSTAR — 33 pens
    TOUJEO SOLOSTAR33 pens per 30 days
    TOUJEO SOLOSTAR (1 unit dial)66 pens per 30 days for 1-unit dial formulation
    TierDrug Tier = 2
    inv-101: TOUJEO SOLOSTAR (1 unit dial) — 66 pens
    TOUJEO SOLOSTAR (1 unit dial)66 pens per 30 days
    ContextHigher QL for 1-unit dial formulation as listed
    TierDrug Tier = 2
    inv-102: SYNJARDY / XIGDUO XR / TRIJARDY XR — 30-60 tablets
    SYNJARDY / XIGDUO XR / TRIJARDY XR30-60 tablets per 30 days depending on strength
    TierDrug Tier = 2
    VariationSome strengths flagged QL (30) while others QL (60)
    inv-103: polyethylene glycol / bowel prep kits — OTC or unspecified QL depending on product
    Polyethylene glycol / bowel prep kitsOTC or unspecified QL depending on product (e.g., PEG-PREP kits vs OTC PEG 3350 powder)
    ExamplesPEG-PREP kits (no QL specified) vs polyethylene glycol 3350 powder (OTC)
    Tier/flagSome listed as ACA and OTC depending on product
    inv-104: ENDOMETRIN (progesterone vaginal insert) — 84 suppositories
    ENDOMETRIN quantity limit84 suppositories per 28 days
    FormulationProgesterone vaginal insert 100 mg
    TierListed under VAGINAL PRODUCTS with QL (84 suppositories/28 days)
    inv-105: Glucose test strips (various brands) — 204
    Glucose test strips common QL204 strips per 30 days
    Applies to brandsCONTOUR, FREESTYLE, PRECISION XTRA, PRECISION NEO B, OPTIUMEZ and others listed with QL 204/30 days
    Requirements/Limits flagOTC, QL (204 strips/30 days)
    inv-106: buprenorphine hcl-naloxone hcl SL film — various (e.g., 120 films/30 days; 60 films/30 days)
    Buprenorphine SL film/tablet limitsVarious QLs depending on formulation (e.g., 120 films/30 days; 60 films/30 days; 120 tablets/30 days; 90 tablets/30 days)
    ExamplesSuboxone films QL (120 films/30 days or 60 films/30 days depending on strength); ZUBSOLV tablets QL (30-90 tablets/30 days)
    Special flagsExtended-release buprenorphine products (BRIXADI, SUBLOCADE) are LA/SP
    inv-107: ZUBSOLV tablets — 30-90 tablets/30 days depending on strength
    ZUBSOLV tablets QL30-90 tablets per 30 days depending on strength (examples shown across ZUBSOLV listings)
    TierDrug Tier = 2* in listings
    ContextMultiple strengths carry different QLs (30, 60, 90 per 30 days)
    inv-108: Glucose test strips (duplicate reference) — 204
    Glucose test strips (duplicate)204 strips per 30 days
    Representative brandsFREESTYLE LITE, OPTIUMEZ, PRECISION XTRA listed with QL 204/30 days
    FlaggingRequirements/Limits = OTC, QL (204 strips/30 days)
    inv-109: Dexcom G6/G7 sensors — 3 sensors (G6/G7)
    Dexcom G6/G7 sensors3 sensors per 30 days (G6/G7) — 3 sensors/30 days
    G7 15-day variant2 sensors per 30 days for Dexcom G7 15-day sensor variant
    ST flagSensors and related items may also show ST (step therapy)
    inv-110: Dexcom G6/G7 receivers/transmitters — 1 receiver/365 days; 1 transmitter/90 days
    Dexcom receivers/transmitters limits1 receiver per 365 days; 1 transmitter per 90 days (transmitter QL listed as 1 transmitter/90 days)
    Receiver examplesDEXCOM G6 RECEIVER and DEXCOM G7 RECEIVER shown with QL (1 receiver/365 days)
    Transmitter examplesDEXCOM G6 TRANSMITTER listed with QL (1 transmitter/90 days)
    inv-111: Omnipod pods — 30 pods/30 days
    Omnipod pods limit30 pods per 30 days
    Kit flagOmnipod kits listed with PA and QL (1 kit/720 days) for intro kits
    TierDrug Tier = 2 for pods and kits
    inv-112: V-GO disposable pump systems — 30 systems/30 days
    V-GO disposable pump systems30 systems per 30 days
    RequirementsV-GO lines list PA and QL (30 systems/30 days)
    V-GO modelsV-GO 20/30/40 systems listed with QL 30 systems/30 days
    inv-113: Ilet/Omnipod starter kits — 1 kit/720 days
    Ilet/Omnipod starter kits limit1 kit per 720 days
    ExamplesOMNIPOD DASH INTRO KIT and OMNIPOD 5 kits flagged PA, QL (1 kit/720 days)
    PA requirementStarter/intro kits require PA when listed
    inv-114: TWIIST refill kit — 1 kit/30 days
    TWIIST refill kit1 kit per 30 days
    Example listingTWIIST REFILL KIT listed with QL (1 kit/30 days)
    Provider actionPA required if product row indicates PA in Requirements/Limits
    inv-115: V-GO 20/30/40 systems — 30 systems
    V-GO 20/30/40 systems30 systems per month (QL 30 systems/30 days)
    RequirementsListed with PA and QL in some entries; follow Requirements/Limits field
    ExamplesV-GO 20, V-GO 30, V-GO 40 each shown with QL (30 systems/30 days)

    Site of Care and Specialty Handling

    Note
    Note

    Background and Scope

    Background: This document is the EmblemHealth PPO Preferred Plan formulary (list of covered drugs) effective 2026-04-01. The formulary lists both brand and generic drugs and assigns each a Drug Tier (for example, ACA for certain preventive drugs). The formulary may change over time as generics become available or products are added or removed. For plan‑specific coverage, copay, or benefit questions, refer to the member’s Certificate of Coverage or contact EmblemHealth Member Services at 833-998-5430 (TTY: 711).